PET imaging of amyloid in Alzheimer's disease

Lancet Neurology

Volumn 3, Issue 9, 2004, Pages 519-527

  Nordberg, Agneta ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE; AMYLOID BETA PROTEIN; CARBON 11; CONGO RED; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT; STILBENE; THIOFLAVINE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; FLUORESCENT DYE;

ALZHEIMER DISEASE; AUTOPSY; BRAIN TISSUE; DEMENTIA; DISEASE COURSE; EXPERIMENTAL ANIMAL; HUMAN; HYPOTHESIS; ISOTOPE LABELING; LABORATORY TEST; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS; SYNAPSE; VACCINATION; ANIMAL; BRAIN; COMPUTER ASSISTED EMISSION TOMOGRAPHY; MOUSE; PATHOLOGY; SCINTISCANNING; SENILE PLAQUE;

ALZHEIMER DISEASE; ANIMALS; BRAIN; FLUORESCENT DYES; HUMANS; INDICATORS AND REAGENTS; MICE; SENILE PLAQUES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 4644283049     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(04)00853-1     Document Type: Review

References (80)

1. Wimo A, Winblad B, Aguero-Torres H, von Strauss E. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord. 17:2003;63-67
2. Alzheimer A. Über einen eigenartigen schweren Erkrankungsprozess der Hirnrinde. Neurologisches Centralblatt. 23:1906;1129-1136
3. Maurer K, Volk S, Gerbaldo H. Auguste D and Alzheimer's disease. Lancet. 349:1997;1546-1549
4. Nordberg A. Neuroreceptor changes in Alzheimer disease. Cerebrovasc Brain Metab Rev. 4:1992;303-328
5. Perry EK. The cholinergic hypothesis - ten years on. Br Med Bull. 42:1986;63-69
6. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 120:1984;885-890
7. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA. 82:1985;4245-4249
8. Wisniewski HM, Wegiel J, Kotula L. David Oppenheimer memorial lecture 1995: some neuropathological aspects of Alzheimer's disease and its relevance to other disciplines. Neuropathol Appl Neurobiol. 22:1996;3-11
9. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82:1991;239-259
10. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 58:2002;1791-1800
11. Braak H, Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm Suppl. 53:1998;127-140
12. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 256:1992;184-185
13. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297:2002;353-356
14. Mullan M, Crawford F, Axelman K, et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet. 1:1992;345-347
15. Kalaria RN, Cohen DL, Greenberg BD, et al. Abundance of the longer A beta 42 in neocortical and cerebrovascular amyloid beta deposits in Swedish familial Alzheimer's disease and Down's syndrome. Neuroreport. 7:1996;1377-1381
16. Citron M, Oltersdorf T, Haass C, et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature. 360:1992;672-674
17. Mann DM, Iwatsubo T, Ihara Y, et al. Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Am J Pathol. 148:1996;1257-1266
18. Näslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 283:2000;1571-1577
19. Parvathy S, Davies P, Haroutunian V, et al. Correlation between Aβx-40-, Aβx-42-, and Aβx-43-containing amyloid plaques and cognitive decline. Arch Neurol. 58:2001;2025-2032
20. Selkoe DJ. Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J Clin Invest. 110:2002;1375-1381
21. Cummings BJ, Cotman CW. Image analysis of beta-amyloid load in Alzheimer's disease and relation to dementia severity. Lancet. 346:1995;1524-1528
22. Schott JM, Fox NC, Frost C, et al. Assessing the onset of structural change in familial Alzheimer's disease. Ann Neurol. 53:2003;181-188
23. Kennedy AM, Frackowiak RS, Newman SK, et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci Lett. 186:1995;17-20
24. Nordberg A, Viitanen M, Almkvist O, et al. Longitudinal positron emission tomographic studies in families with chromosome 14 and 21 encoded Alzheimer's disease. Iqbal K, Mortimer J, Winblad H. Research advances in Alzheimer's disease and related disorders. 1995;243-249 John Wiley & Sons, Chichester
25. Wahlund LO, Basun H, Almkvist O, et al. A follow-up study of the family with the Swedish APP 670/671 Alzheimer's disease mutation. Dement Geriatr Cogn Disord. 10:1999;526-533
26. Small GW, Ercoli LM, Silverman DH, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA. 97:2000;6037-6042
27. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci USA. 98:2001;3334-3339
28. Reiman EM, Chen K, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci USA. 101:2004;284-289
29. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 56:1999;303-308
30. Grundman M, Petersen RC, Ferris SH, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 61:2004;59-66
31. Arnaiz E, Jelic V, Almkvist O, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment,. Neuroreport. 12:2001;851-855
32. Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology. 60:2003;1374-1377
33. Wolf H, Jelic V, Gertz HJ, Nordberg A, Julin P, Wahlund LO. A critical discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurol Scand Suppl. 179:2003;52-76
34. DeKosky ST, Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science. 302:2003;830-834
35. Nordberg A. Toward an early diagnosis and treatment of Alzheimer's disease. Int Psychogeriatr. 15:2003;223-237
36. Nordberg A. Functional studies of cholinergic activity in normal and Alzheimer disease states by imaging technique. Prog Brain Res. 145:2004;301-310
37. Jagust W. The proteomics of positron emission tomography. Ann Neurol. 55:2004;303-305
38. Klunk WE, Engler H, Nordberg A, et al. Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. Cidis Meltzer C. Neurologic applications of positron emission tomography. 2003;781-789 W Saunders Company, Philadelphia
39. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 55:2004;306-319
40. Friedland RP, Kalaria R, Berridge M, et al. Neuroimaging of vessel amyloid in Alzheimer's disease. Ann NY Acad Sci. 826:1997;242-247
41. Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 10:2002;24-35
42. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 46:2003;2740-2754
43. Poduslo JF, Wengenack TM, Curran GL, et al. Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis. 11:2002;315-329
44. Wadghiri YZ, Sigurdsson EM, Sadowski M, et al. Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med. 50:2003;293-302
45. Mathis CA, Bacskai BJ, Kajdasz ST, et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett. 12:2002;295-298
46. Bacskai BJ, Kajdasz ST, Christie RH, et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med. 7:2001;369-372
47. Bacskai BJ, Hickey GA, Skoch J, et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci USA. 100:2003;12462-12467
48. Maggio JE, Stimson ER, Ghilardi JR, et al. Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide. Proc Natl Acad Sci USA. 89:1992;5462-5466
49. Friedland RP, Majocha RE, Reno JM, Lyle LR, Marotta CA. Development of an anti-A beta monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease. Mol Neurobiol. 9:1994;107-113
50. Lee HJ, Zhang Y, Zhu C, Duff K, Pardridge WM. Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. J Cereb Blood Flow Metab. 22:2002;223-231
51. Zhuang ZP, Kung MP, Wilson A, et al. Structure-activity relationship of imidazo[1,2-a]pyridines as ligands for detecting beta-amyloid plaques in the brain. J Med Chem. 46:2003;237-243
52. Wengenack TM, Curran GL, Poduslo JF. Targeting alzheimer amyloid plaques in vivo. Nat Biotechnol. 18:2000;868-872
53. Lovat LB, Persey MR, Madhoo S, Pepys MB, Hawkins PN. The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients. Gut. 42:1998;727-734
54. Lovat LB, O'Brien AA, Armstrong SF, et al. Scintigraphy with 123I-serum amyloid P component in Alzheimer disease. Alzheimer Dis Assoc Disord. 12:1998;208-210
55. Friedland RP, Shi J, Lamanna JC, Smith MA, Perry G. Prospects for noninvasive imaging of brain amyloid beta in Alzheimer's disease. Ann NY Acad Sci. 903:2000;123-128
56. Bornebroek M, Verzijlbergen JF, Haan J, et al. Potential for imaging cerebral amyloid deposits using 123I-labelled serum amyloid P component and SPET. Nucl Med Commun. 17:1996;929-933
57. Shi J, Perry G, Berridge MS, et al. Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. J Nucl Med. 43:2002;1044-1051
58. Benveniste H, Einstein G, Kim KR, Hulette C, Johnson GA. Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc Natl Acad Sci USA. 96:1999;14079-14084
59. Dhenain M, Privat N, Duyckaerts C, Jacobs RE. Senile plaques do not induce susceptibility effects in T2*-weighted MR microscopic images. NMR Biomed. 15:2002;197-203
60. Klunk WE, Debnath ML, Pettegrew JW. Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease. Neurobiol Aging. 15:1994;691-698
61. Klunk WE, Debnath ML, Pettegrew JW. Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe. Neurobiol Aging. 16:1995;541-548
62. Styren SD, Hamilton RL, Styren GC, Klunk WE. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology. J Histochem Cytochem. 48:2000;1223-1232
63. Link CD, Johnson CJ, Fonte V, et al. Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. Neurobiol Aging. 22:2001;217-226
64. Zhuang ZP, Kung MP, Hou C, et al. Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. J Med Chem. 44:2001;1905-1914
65. Kung MP, Hou C, Zhuang ZP, et al. Radioiodinated styrylbenzene derivatives as potential SPECT imaging agents for amyloid plaque detection in Alzheimer's disease. J Mol Neurosci. 19:2002;7-10
66. Klunk WE, Bacskai BJ, Mathis CA, et al. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol. 61:2002;797-805
67. Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Mathis CA. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci. 69:2001;1471-1484
68. Wang Y, Klunk WE, Huang GF, Debnath ML, Holt DP, Mathis CA. Synthesis and evaluation of 2-(3′-iodo-4′-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in Alzheimer's disease. J Mol Neurosci. 19:2002;11-16
69. Klunk WE, Wang Y, Huang GF, et al. The binding of 2-(4′- methylaminophenyl) benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci. 23:2003;2086-2092
70. Kung MP, Zhuang ZP, Hou C, Jin LW, Kung HF. Characterization of radioiodinated ligand binding to amyloid beta plaques. J Mol Neurosci. 20:2003;249-254
71. Lee CW, Kung MP, Hou C, Kung HF. Dimethylamino-fluorenes: ligands for detecting beta-amyloid plaques in the brain. Nucl Med Biol. 30:2003;573-580
72. Kung MP, Hou C, Zhuang ZP, Cross AJ, Maier DL, Kung HF. Characterization of IMPY as a potential imaging agent for beta-amyloid plaques in double transgenic PSAPP mice. Eur J Nucl Med Mol Imaging 2004; published online March 9.
73. Kung HF, Lee CW, Zhuang ZP, Kung MP, Hou C, Plossl K. Novel stilbenes as probes for amyloid plaques. J Am Chem Soc. 123:2001;12740-12741
74. Kung HF, Kung MP, Zhuang ZP, et al. Iodinated tracers for imaging amyloid plaques in the brain. Mol Imaging Biol. 5:2003;418-426
75. Ono M, Wilson A, Nobrega J, et al. 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. Nucl Med Biol. 30:2003;565-571
76. Suemoto T, Okamura N, Shiomitsu T, et al. In vivo labeling of amyloid with BF-108. Neurosci Res. 48:2004;65-74
77. Agdeppa ED, Kepe V, Liu J, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci. 21:2001;RC189
78. Agdeppa ED, Kepe V, Liu J, et al. 2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease. Mol Imaging Biol. 5:2003;404-417
79. Bresjanac M, Smid LM, Vovko TD, Petric A, Barrio JR, Popovic M. Molecular-imaging probe 2-(1-[6-[(2-fluoroethyl)(methyl) amino]-2-naphthyl] ethylidene) malononitrile labels prion plaques in vitro. J Neurosci. 23:2003;8029-8033
80. Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR. "Preclinical" AD revisited: neuropathology of cognitively normal older adults. Neurology. 55:2000;370-376